Tetrapeptide-30 – CAS 1036207-61-0
Tetrapeptide-30 is a four-amino-acid spot-correcting peptide with a molecular weight of approximately 550 Da. Identified by CAS number 1036207-61-0, this peptide targets the melanogenesis pathway upstream of tyrosinase, offering a fundamentally different and safer approach to skin brightening compared to conventional depigmenting agents like hydroquinone or kojic acid. Its mechanism centres on inhibiting MITF (microphthalmia-associated transcription factor), the master regulator of melanocyte activation.
Mechanism of Action
Most brightening agents work by directly inhibiting tyrosinase, the enzyme that converts tyrosine to melanin. Tetrapeptide-30 operates one level higher in the signalling cascade by suppressing MITF transcription factor activity. MITF controls the expression of tyrosinase, TRP-1, and TRP-2, meaning that blocking MITF simultaneously downregulates multiple melanin-producing enzymes rather than just one. This upstream intervention reduces melanin output without the cytotoxic effects on melanocytes that have led to safety concerns with hydroquinone. The melanocytes remain viable and functional; they simply produce less pigment.
Efficacy Data
In cell culture assays using human melanocytes, Tetrapeptide-30 at 100 ppm reduced melanin content by 38% compared to untreated controls without measurable cytotoxicity. Cell viability remained above 95% throughout the study period, confirming the peptide does not achieve depigmentation through melanocyte damage. This safety-efficacy profile positions Tetrapeptide-30 as a compelling alternative for formulators reformulating away from hydroquinone in compliance with EU Cosmetics Regulation restrictions.
Formulation Guidelines
Incorporate Tetrapeptide-30 at 50-200 ppm in the aqueous phase. The peptide is water-soluble and stable at pH 5.0-7.0. It integrates smoothly into brightening serums, spot treatments, and day creams. For enhanced efficacy, combine with complementary brightening agents such as niacinamide (vitamin B3), alpha-arbutin, or tranexamic acid to target melanogenesis at multiple points in the pathway. Avoid pairing with strong reducing agents like ascorbic acid at low pH, which may degrade the peptide bond. Process below 40 degrees C and protect from prolonged light exposure during manufacturing.
Applications
- Targeted spot-correcting serums for hyperpigmentation and melasma
- Brightening day creams with SPF for prevention of new dark spots
- Post-inflammatory hyperpigmentation treatments for acne-prone skin
- Even-tone body lotions for elbows, knees, and underarm brightening
- Professional depigmenting protocols in clinical aesthetics settings
Regulatory Advantage
Hydroquinone is banned in cosmetic products within the EU (Annex II of Regulation 1223/2009) and increasingly restricted globally. Tetrapeptide-30 provides formulators with a peptide-based depigmenting mechanism that carries no such regulatory burden. Its non-cytotoxic profile and peptide classification simplify safety documentation for cosmetic product notification on the CPNP portal.
Quality and Supply from TCS NEXUS S.L.
TCS NEXUS S.L. supplies Tetrapeptide-30 from Valencia, Spain with HPLC purity of 98% minimum. Every batch includes a certificate of analysis documenting identity by mass spectrometry, purity by HPLC, peptide content, and microbial limits. We stock for rapid European dispatch and accept orders from development-scale to multi-kilogram production volumes. Full regulatory support documentation is available upon request.
Frequently Asked Questions
How does Tetrapeptide-30 compare to hydroquinone?
Tetrapeptide-30 inhibits MITF to reduce melanin production without cytotoxicity, while hydroquinone directly damages melanocytes. Tetrapeptide-30 reduced melanin 38% at 100 ppm with over 95% cell viability, making it a safer long-term option.
Can Tetrapeptide-30 be combined with other brightening ingredients?
Yes. It pairs effectively with niacinamide, alpha-arbutin, and tranexamic acid for multi-target depigmentation. Avoid combining with low-pH ascorbic acid formulations that may hydrolyse the peptide.
Is Tetrapeptide-30 permitted in EU cosmetics?
Yes. Unlike hydroquinone, Tetrapeptide-30 is not listed on Annex II of the EU Cosmetics Regulation. It can be used in cosmetic products subject to standard safety assessment requirements.
Technical Support and Samples
Request COA documents, sample availability, or support for custom synthesis.
Frequently Asked Questions
Do you provide COA documents for Tetrapeptide-30 Supplier Europe?
Yes. Each lot can be supplied with a Certificate of Analysis, HPLC purity data, and relevant quality-control results for technical review.
Are samples available for Tetrapeptide-30 Supplier Europe?
Yes. Sample availability can be confirmed for formulation screening and internal evaluation before a commercial order is placed.
What is the delivery lead time for Tetrapeptide-30 Supplier Europe?
For stocked material in Valencia, EU delivery is typically 5 to 7 business days. Final timing depends on destination and requested volume.
Do you also support custom synthesis and technical inquiries?
Yes. The team can help with custom synthesis, raw-material selection, technical documentation, and supply planning.